Clinical trial
Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
NCT00676715 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 17, 2008
- Completion date
- November 8, 2023
- Enrollment
- 220 (actual)
- Sites
- 84
Conditions
As the registry lists them; a condition with its own page is linked.